The 7 major trauma markets are expected to exhibit a CAGR of 5.78% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2034
|
Historical Years
|
2018-2023
|
Market Growth Rate 2024-2034 | 5.78% |
The trauma market has been comprehensively analyzed in IMARC's new report titled "Trauma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Trauma refers to a psychological or emotional reaction to an overwhelmingly distressing or disturbing event or series of events. These reactions can vary from person to person but often include feelings of intense fear, helplessness, or horror. The condition can cause a range of indications in patients, such as anxiety, depression, nightmares, sensations of detachment, irritability, hypervigilance, intrusive memories or flashbacks of the event, physical pain or discomfort, difficulty sleeping and concentrating, etc. Trauma can also have a profound impact on the patient’s thoughts, emotions, behaviors, and overall functioning. Diagnosing this disease typically involves a comprehensive assessment conducted by a qualified mental healthcare professional, such as a psychiatrist or psychologist. Initially, a doctor will evaluate the patient's symptoms and compare them to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10), which help to rule out alternative explanations and confirm the diagnosis. In severe cases, numerous neurological assessments, like cognitive workups, reflex tests, imaging studies, etc., may be conducted to determine any abnormality or dysfunction within the brain.
The increasing incidences of physical violence, sexual assault, or emotional abuse that can shatter a person's sense of safety, security, and trust in others are primarily driving the trauma market. In addition to this, the inflating utilization of cognitive behavioral therapy, which focuses on detecting and changing negative thoughts and behaviors to alleviate distress as well as promote healing, is creating a positive outlook for the market. Moreover, the widespread adoption of mindfulness-based stress reduction programs that combine meditation, body awareness, and yoga to help in managing anxiety and enhancing overall well-being is further bolstering the market growth. Apart from this, the rising usage of effective drugs, such as benzodiazepines, antipsychotics, anesthetics, etc., since they work by increasing the levels of both serotonin and norepinephrine to promote calmness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of eye movement desensitization and reprocessing techniques, which aid patients in dealing with distressing memories to reduce their emotional impact and enable adaptive resolution, is expected to drive the trauma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the trauma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for trauma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the trauma market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current trauma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Human acellular vessel | Humacyte |
MultiStem | Athersys |
ASTOPC1 | Lineage Cell Therapeutics |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Trauma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies